Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (a joint stock limited company incorporated in the People’s Republic of China with limited liability) (Stock Code: 02196)

CHANGE OF CHAIRMAN AND AUTHORISED REPRESENTATIVE RE-DESIGNATION OF DIRECTORS AND ADJUSTMENT OF SENIOR MANAGEMENT

The Board hereby announces that:

(1) Mr. Chen Qiyu resigned as Chairman and Authorised Representative with effect from 29 October 2020 ;

(2) Mr. Yao Fang resigned as co-chairman with effect from 29 October 2020;

(3) Mr. Wu Yifang has been elected as Chairman of the eighth session of the Board and Mr. Wu Yifang has been appointed as the Authorised Representative with effect from 29 October 2020;

(4) Mr. Chen Qiyu and Mr. Yao Fang will be re-designated from executive Directors to non- executive Directors with effect from 29 October 2020; and

(5) Mr. Wu Yifang resigned as president of the Company; Mr. Chen Yuqing, Mr. Wang Kexin and Mr. Li Dongming were appointed as the co-president of the Company and Ms. Guan Xiaohui was appointed as the executive president and the chief financial officer of the Company, such resignation and appointments shall take effect from 29 October 2020.

– 1 – CHANGE OF CHAIRMAN AND AUTHORISED REPRESENTATIVE

On 29 October 2020, the board (the ‘‘Board’’)ofdirectors(the‘‘Directors’’) of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the ‘‘Company’’, together with its subsidiaries, the ‘‘Group’’) received the resignation letters from Mr. Chen Qiyu (‘‘Mr. Chen’’) and Mr. Yao Fang (‘‘Mr.Yao’’), executive Directors. Mr. Chen resigned as (i) chairman of the eight session of the Board (the ‘‘Chairman’’); and (ii) an authorised representative of the Company (the ‘‘Authorised Representative’’) for the purpose of Rule 3.05 of the Rules Governing the Listing of Securities (the ‘‘Hong Kong Listing Rules’’) on The Stock Exchange of Hong Kong Limited (the ‘‘’’) due to work arrangements. Mr. Yao resigned as co-chairman of the Company due to work arrangements. In accordance with the articles of association of the Company (the ‘‘Articles of Association’’), the resignations of Mr. Chen and Mr. Yao shall become effective from 29 October 2020.

Mr. Chen and Mr. Yao have confirmed that there are no disagreements between them and the Board during their term of office and there are no matter relating to their resignations that need to be brought to the attention of the shareholders of the Company (the ‘‘Shareholders’’).

The Board hereby expresses its gratitude to Mr. Chen and Mr. Yao for their valuable contributions during their term of office.

The Board announces that Mr. Wu Yifang (‘‘Mr. Wu’’) was elected as the Chairman for a term of office from 29 October 2020 until the expiration of the eighth session of the Board. In accordance with the Articles of Association, Mr. Wu will serve as the legal representative of the Company. The Board also announces that Mr. Wu was appointed as the Authorised Representative with effect from 29 October 2020. Mr. Wu and Ms. Kam Mei Ha Wendy will jointly perform related duties of the Authorised Representative.

Mr. Wu, born in April 1969, joined the Group in April 2004, served as the senior vice president of the Company from July 2014 to January 2016, the senior vice president and chief operating officer of the Company from January 2016 to June 2016, the president of the Company from June 2016 to October 2020, an executive Director since August 2016 and the chief executive officer of the Company (the ‘‘CEO’’) since June 2016, and serves as directors of several subsidiaries of the Company. Mr. Wu is currently the non-executive director of Sisram Medical Ltd (stock code: 01696) and Shanghai Henlius Biotech, Inc. (stock code: 02696) (‘‘Shanghai Henlius’’), and the chairman of the supervisory committee of Co., Ltd.* (國藥控股股份有限公司)(‘‘Sinopharm’’)(stockcode: 01099), all of which are companies listed on the Hong Kong Stock Exchange. Mr. Wu worked as a technician, director, production officer, finance director, assistant to factory director of Xuzhou Biochemical Pharmaceutical Factory* (徐州生物化學製藥廠)(‘‘Xuzhou Biochemical’’), a deputy factory director of Xuzhou (Wanbang) Biochemical Pharmaceutical Manufactures Factory* (徐州(萬邦) 生物化學製藥廠)(‘‘Xuzhou (Wangbang) Biochemical’’), a deputy general manager of Xuzhou Wanbang Biochemical Pharmaceutical Co., Ltd.* (徐州萬邦生化製藥有限公司)(‘‘Xuzhou Wangbang Biochemical’’) and Jiangsu Wanbang Biochemical Pharmaceutical Co., Ltd.* (江蘇萬邦生化醫藥股份 有限公司)(‘‘Jiangsu Wanbang Biochemical’’), president of Jiangsu Wanbang Biochemical (where

– 2 – Xuzhou Biochemical, Xuzhou (Wanbang) Biochemical, Xuzhou Wanbang Biochemical and Jiangsu Wanbang Biochemical were predecessors of Jiangsu Wanbang (Group) Biochemical Pharmaceutical Co., Ltd.* (江蘇萬邦生化醫藥集團有限責任公司)), and the chairman of Jiangsu Wanbang Biochemical Pharmaceutical Co., Ltd.*. Mr. Wu graduated from Nanjing University of Science and Technology (南 京理工大學) majoring in international trade in 1996 and obtained a master degree in business administration from Saint Joseph’s University in 2005.

As at the date of this announcement, Mr. Wu has personal interests in 1,060,900 shares of the Company (the ‘‘Shares’’), 718,900 A shares (the ‘‘A Shares’’) and 342,000 H shares (the ‘‘HShares’’) within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the ‘‘SFO’’), representing approximately 0.04% of the total number of issued Shares. Save as disclosed above, Mr. Wu is not interested or deemed to be interested in any Shares or underlying Shares within the meaning of Part XV of the SFO.

As at the date of this announcement, Mr. Wu has entered into a service contract as an executive Director with the Company. As Mr. Wu also serves as the CEO, he will continue to receive remuneration from the Company based on his senior management positions, and will not receive any remuneration from the Company for his position as an executive Director.

Save as disclosed above, Mr. Wu does not hold any directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the three years immediately prior to the date of his appointment. As at the date of this announcement, Mr. Wu does not have any relationship with any director, senior management, substantial shareholder or controlling shareholder of the Company.

Save as disclosed above, there is no other matter relating to the appointment of Mr. Wu as the Chairman that needs to be brought to the attention of the Shareholders and there is no other information that needs to be disclosed in connection with Mr. Wu’s appointment as a Chairman pursuant to the requirements of Rule 13.51(2) of the Hong Kong Listing Rules.

DEVIATION FROM THE CORPORATE GOVERNANCE CODE

As Mr. Wu serves as both Chairman and CEO, such practice deviates from code provision A.2.1 of the Corporate Governance Code as set forth in Appendix 14 to Hong Kong Listing Rules (the ‘‘CG Code’’). Code provision A.2.1 of the CG Code provides that the roles of chairman and chief executive should be separate and should not be performed by the same individual.

Mr. Wu joined the Group in April 2004 and has been successively serving in key positions in management and operation of subsidiaries of the Company and the Company since 2016. Although Mr. Wu serving as both the Chairman and CEO will deviate from code provision A.2.1, his familiarity with business operation of the Group and the role of Chairman and CEO vested in him can facilitate the implementation of business strategies of the Group. Further, the Board considered that the current structure will not impair the balance of power and authority between the Board and the management of the Group. The Board will make decisions on important matters of the Company within the authority

– 3 – granted by the Articles of Association and Shareholders at the general meetings. Further, the Board (comprises one executive Director, six non-executive Director and four independent non-executive Directors) is appropriately structured with a balance of power to provide sufficient checks to protect the interests of the Company and the Shareholders as a whole. Accordingly, the Board considers that the deviation from the Code Provision A.2.1 is appropriate in such circumstances.

RE-DESIGNATION OF EXECUTIVE DIRECTORS TO NON-EXECUTIVE DIRECTORS

The Board hereby announces that Mr. Chen and Mr. Yao will be re-designated from executive Directors to non-executive Directors for a term of office from 29 October 2020 until the expiry of the eighth session of the Board.

Mr. Chen, born in April 1972, joined the Group in April 1994, and was appointed as a Director in May 2005. Mr. Chen served as an executive Director and the Chairman from June 2010 to October 2020, and serves as a director of several subsidiaries of the Company. Mr. Chen is currently the chairman of Shanghai Fosun High Technology (Group) Company Limited* (上海復星高科技(集團)有限公司). Mr. Chen is also an executive director and a co-chief executive officer of Limited (stock code: 00656), a non-executive director and vice chairman of Sinopharm (stock code: 01099), a non-executive director of Babytree Group (stock code: 01761) and a non-executive director and chairman of the board of directors of Shanghai Henlius (stock code: 02696), all of which are companies listed on the Hong Kong Stock Exchange. He is also a director of Beijing Sanyuan Foods Co., Ltd* (北京三元食品股份有限公司) (stock code: 600429), a company listed on the , and a co-chairman of New Frontier Health Corporation, a company listed on the New York Stock Exchange (stock code: NFH). Mr. Chen was a director of Maxigen Biotech Inc. (stock code: 1783), a company listed on the Taiwan Stock Exchange and a director of Di’an Diagnostics Group Co., Ltd.* (迪安診斷技術集團股份有限公司) (stock code: 300244), a company listed on the growth enterprise board of the Shenzhen Stock Exchange. Mr. Chen is also the chairman of China Medical Pharmaceutical Material Association* (中國醫藥物資協會), vice president of China Pharmaceutical Industry Research and Development Association* (中國醫藥創新促進會), honorary chairman and chief supervisor of the Shanghai Biopharmaceutical Industry Association* (上海市生物醫藥行業協會), vice chairman of the Shanghai Society of Genetics* (上海市遺傳學會) and a member of the 13th Shanghai Standing Committee of the Chinese People’s Political Consultative Conference. Mr. Chen obtained a bachelor degree in genetics from Fudan University (復旦大學) in July 1993 and an executive master of business administration from China Europe International Business School (中歐國際工商學院)in September 2005.

– 4 – Mr. Yao, born in July 1969, joined the Group in April 2010 and was appointed as a Director in June 2010. Mr. Yao served as the executive Director, president, CEO, vice chairman and co-chairman of the Company from June 2010 to October 2020, and serves as a director of certain subsidiaries of the Company. Prior to joining the Group, from 1993 to 2009, Mr. Yao was successively the assistant general manager of the international business department of Shanghai Wanguo Securities Company Limited* (上海萬國證券有限公司), now known as Shenwan Hongyuan Group Co., Ltd.* (申萬宏源集 團股份有限公司), general manager of Shanghai Industrial Assets Management Company Limited* (上 海上實資產經營有限公司), general manager of Shanghai Industrial Management (Shanghai) Company Limited* (上實管理(上海)有限公司), managing director of Shanghai Industrial Pharmaceutical Investment Company Limited* (上海實業醫藥投資股份有限公司), a company delisted from the Shanghai Stock Exchange on 12 February 2010, chairman of Shanghai Overseas Company* (上海海外 公司), non-executive director of Lianhua Supermarket Holdings Co., Ltd.* (聯華超市股份有限公司) (stock code: 00980), a company listed on the Hong Kong Stock Exchange, and executive director of Shanghai Industrial Holdings Limited* (上海實業控股有限公司) (stock code: 00363), a company listed on the Hong Kong Stock Exchange. Mr. Yao was a non-executive director of Biosino Bio-Technology and Science Incorporation (中生北控生物科技股份有限公司) (stock code: 08247), and the chairman of the supervisory committee of Sinopharm (stock code: 01099), both of which are companies listed on the Hong Kong Stock Exchange. Mr. Yao obtained a bachelor degree of economics from Fudan University (復旦大學) in July 1989 and a master degree of business administration from The Chinese University of Hong Kong in December 1993.

As at the date of this announcement, within the meaning of Part XV of the SFO, Mr. Chen has personal interests in 114,075 A Shares, representing 0.004% of the total issued Shares; Mr. Yao has personal interests in 781,000 A Shares, representing 0.03% of the total issued Shares. Save as disclosed above, Mr. Chen and Mr. Yao were not interested or deemed to be interested in any shares or underlying shares of the Company pursuant to Part XV of the SFO.

As at the date of this announcement, the Company has entered into appointment letters with Mr. Chen and Mr. Yao as non-executive Directors. The term of office of Mr. Chen and Mr. Yao as non-executive Directors will be effect from 29 October 2020, until the expiration of the term of the eighth session of the Board. Mr. Chen and Mr. Yao will not receive any remuneration from the Company for their non- executive directorships.

Save as disclosed above, Mr. Chen and Mr. Yao do not hold any directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the three years immediately prior to the date of their appointment. As at the date of this announcement, save as disclosed above, Mr. Chen and Mr. Yao do not have any relationship with any Director, senior management, substantial shareholder or controlling shareholder of the Company.

Save as disclosed above, there is no other matter relating to re-designation of Mr. Chen and Mr. Yao to non-executive Directors that needs to be brought to the attention of the Shareholders and there is no other information that needs to be disclosed in connection with re-designation of Mr. Chen and Mr. Yao to non-executive Directors pursuant to the requirements of Rule 13.51(2) of the Hong Kong Listing Rules.

– 5 – ADJUSTMENT OF SENIOR MANAGEMENT

On 29 October 2020, the Board received the resignation letter from Mr. Wu to resign as the president of the Company. The resignation of Mr. Wu was effective upon the delivery of the resignation letter to the Board. After the resignation of president, Mr. Wu will serve as executive Director, Chairman and CEO.

On the same day, based on the nomination of CEO, the Board appointed Mr. Chen Yuqing, Mr. Wang Kexin and Mr. Li Dongming as the co-presidents of the Company, and appointed Ms. Guan Xiaohui as the executive president and the chief financial officer of the Company. Each of their term of office shall commence from 29 October 2020 and end on the expiry of the eighth session of the Board.

The biographical details of such senior management are set out as follows:

1. Mr. Chen Yuqing (陳玉卿), born in December 1975, joined the Group in January 2010. He served as the vice president of the Company from April 2015 to June 2016 and the senior vice president from June 2016 to October 2020. Prior to joining the Group, Mr. Chen Yuqing was the chief human resources officer of Kubao Information Technology (Shanghai) Co., Ltd.* (酷寶信息技 術(上海)有限公司).

2. Mr. Wang Kexin (王可心), born in February 1962, joined the Group in June 2010. He served as the vice president of the Company from July 2011 to July 2016 and the senior vice president of the Company from July 2016 to October 2020. Prior to joining the Group, Mr. Wang Kexin was the vice president of Chongqing Huali Pharmaceutical Industry Company Limited* (重慶華立藥業 股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 000607).

3. Mr. Li Dongming (李東明), born in September 1969, joined the Group in April 2017. Mr. Li Dongming served as the vice president of the Company from January 2018 to September 2020 and the senior vice president of the Company from September 2020 to October 2020. Prior to joining the Group, Mr. Li Dongming was a technician trainee, deputy director, director, and the assistant to the plant manager and director in the workshop of Shanghai Yan’an Pharmaceutical Plant* (上 海延安製藥廠), a deputy general manager and director of the human resources department of Shanghai Yan’an Wanxiang Pharmaceutical Co., Ltd.* (上海延安萬象藥業股份有限公司), a deputy factory director of Shanghai Sine Pharmaceuticals* (信誼藥廠) (now known as Shanghai SPH Sine Pharmaceutical Laboratories Co., Ltd.* (上海上藥信誼藥廠有限公司)), the strategic director of the strategy and investment committee office under the board of directors, as well as the vice president of the OTC sales business department of Shanghai Pharmaceuticals (Group) Limited* (上海醫藥（集團）有限公司), a director and deputy general manager of Shanghai Roche Pharmaceutical Co., Ltd.* (上海羅氏製藥有限公司), a director and general manager of Shanghai Zhongxi Sunve Pharmaceutical Co., Ltd.* (上海中西三維藥業有限公司), and a director and general manager of Shanghai Pharmaceutical Group Pharma Sales Co., Ltd.* (上海醫藥集團藥品 銷售有限公司).

– 6 – 4. Ms. Guan Xiaohui (關曉暉), born in March 1971, joined the Group in May 2000. She served as the chief accountant of the Company from June 2013 to December 2014, the vice president and chief accountant of the Company from December 2014 to June 2015, the senior vice president of the Company from June 2015 to October 2020, and serves as the chief financial officer of the Company since June 2015. Ms. Guan Xiaohui is a non-executive director of companies listed on the Hong Kong Stock Exchange, namely Sinopharm (stock code: 01099) and Shanghai Henlius (stock code: 02696). Prior to joining the Group, Ms. Guan Xiaohui worked at Jiangxi Provincial Branch of the Industrial and Commercial * (中國工商銀行江西省分行). Ms. Guan Xiaohui is qualified as Chinese Certified Public Account (CPA) and a member of The Association of Chartered Certified Accountants (ACCA).

By order of the Board Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* Wu Yifang Chairman

Shanghai, the PRC 29 October 2020

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

* for identification purposes only

– 7 –